Among the different breast cancer subsets, triple-negative breast cancer (TNBC) has the
worst prognosis and limited options for targeted therapies. Immunotherapies are emerging …

Potentiating antitumor immunity is a promising therapeutic approach for treating a variety of
cancers, including breast cancer. One potential strategy to promote antitumor immunity is …

Fifteen novel butyric ester tethered dihydroartemisinin-isatin hybrids 4a-d and 5a-k were
designed, synthesized, and evaluated for cytotoxicity against four human breast cancer cell …

Rationale: An immunosuppressive tumor microenvironment (TME) is a major obstacle in
tumor immunotherapy. Stimulator of interferon genes (STING) agonists trigger an …

Background Currently, the development of breast cancer immunotherapy based on the PD-
1/PD-L1 pathway is relatively slow, and the specific mechanism affecting the immunotherapy …

Background PROS1 is an encoding gene that can generate protein S. This protein is a
glycoprotein found in plasma that conducts physiological functions with vitamin K. However …

Introduction: Artemisia absinthium (wormwood) exhibits anticancer properties by inhibiting
proliferation and causing cell death in breast cancer. Targeted drug-delivery of A …

Purpose Breast cancers exhibit molecular heterogeneity, leading to diverse clinical
outcomes and therapeutic responses. Immune checkpoint inhibitors targeting PD-L1 have …

Triple-negative breast cancer (TNBC) is the most difficult type of breast cancer to treat. TNBC
is defined by the lack of expression of three receptors: estrogen receptor (ER); progesterone …

Cancer cells evolve, acquire resistance to therapy and change their environment. One
resistance mechanism involves altering communication with non-malignant cells in the …